Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Luc Friboulet


Luc Friboulet

Gustave Roussy Cancer Campus


Doctor Luc Friboulet is an ERC starting grant holder and young group leader at Gustave Roussy Cancer Campus, Villejuif, France. He obtained his PhD degree at the Paris-Sud University defending his work on the role of c-IAP2 in TLR3 mediated apoptosis in cancer. His first postdoctoral position, in Jean-Charles Soria’s lab, focused on the function of ERCC1 isoforms in DNA repair to predict patient’s clinical benefit from platinum-based chemotherapy. Luc Friboulet was then trained by Alice Shaw and Jeffrey Engelman at the Massachusetts General Hospital in Boston to study the molecular mechanisms of resistance to ALK kinase inhibitors in lung cancer.

Luc Friboulet is currently working in INSERM UMR981 where his main interest lies in the field of molecular mechanisms of tumor adaptation to kinase inhibitors in solid tumors. He has co-authored several articles in high impact journals such as the New England Journal of Medicine, Science, Cancer Discovery or Cancer Cell.

Last update: June 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.